Bristol James Arthur — SEC insider filings
SEC reporting owner CIK 1715153. 21 insider filings on record with FilingPulse; latest filed 2026-09-01.
Transaction summary — filings shown
Covers all 21 filings on record, filed 2020-10-13 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 20,000 shares, $82,800 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 4 filings — 52,241 shares, $2,580,212 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 19,370 shares @ $53.35 ($1,033,451) in Deciphera Pharmaceuticals, Inc., filed 2020-10-13.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. | Director | 9 | — | 10 legs · 52,241 sh · $2,580,212 | 20 |
| Erasca, Inc. (ERAS) | Director | 9 | 1 leg · 20,000 sh · $82,800 | — | 8 |
| Ernexa Therapeutics Inc. (ERNA) | Director | 3 | — | — | 4 |
Insider filings — Bristol James Arthur
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Ernexa Therapeutics Inc. (ERNA) | Grant/award (A): 8,320 (derivative) @ $0 · Grant/award (A): 5,083 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 29,888 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 37,762 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Eterna Therapeutics Inc. (ERNA) | Grant/award (A): 72,074 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 45,678 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Deciphera Pharmaceuticals, Inc. | Disposition to issuer (D): 22,150 (derivative) · Disposition to issuer (D): 67,494 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 9,570 (derivative) · Disposition to issuer (D): 18,500 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-04-29 | 4 | Eterna Therapeutics Inc. (ERNA) | Grant/award (A): 124,525 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 62,747 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2023-06-23 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-12-22 | 4 | Erasca, Inc. (ERAS) | Purchase (P): 20,000 @ $4.14 | EDGAR |
| 2022-06-24 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Grant/award (A): 18,500 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2022-01-20 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Grant/award (A): 9,570 (derivative) @ $5.22 | EDGAR |
| 2021-06-25 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-04-21 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Option exercise (M): 5,300 @ $3.95 · Sale (S): 4,000 @ $46.13 · Sale (S): 1,300 @ $46.66 · Option exercise (M): 1,700 @ $3.95 · Sale (S): 1,700 @ $45.60 · Option exercise (M): 5,300 (derivative) @ $0 · +1 more | EDGAR |
| 2021-04-14 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Option exercise (M): 14,700 @ $3.95 · Sale (S): 9,483 @ $43.70 · Sale (S): 5,217 @ $44.09 · Option exercise (M): 14,700 (derivative) @ $0 | EDGAR |
| 2021-01-20 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Option exercise (M): 7,000 @ $3.95 · Sale (S): 6,400 @ $50.21 · Sale (S): 600 @ $51.11 · Option exercise (M): 7,000 (derivative) @ $0 | EDGAR |
| 2020-10-13 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Option exercise (M): 23,541 @ $1.89 · Sale (S): 19,370 @ $53.35 · Sale (S): 3,971 @ $54.53 · Sale (S): 200 @ $55.43 · Option exercise (M): 23,541 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1715153 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs